Research programme: proto oncogene proteins c-akt inhibitors - Merck & Co

Drug Profile

Research programme: proto oncogene proteins c-akt inhibitors - Merck & Co

Alternative Names: Protein kinase B inhibitors - Merck & Co

Latest Information Update: 30 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Naphthyridines; Pyridines
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 30 Aug 2011 No development reported - Preclinical for Cancer in USA (IV)
  • 04 Sep 2008 Preclinical safety and pharmacodynamics data in Cancer presented at the 20th International Symposium on Medicinal Chemistry (ISMC-2008)
  • 03 Sep 2008 Interim pharmacodynamics and pharmacokinetics data from a preclinical trial in Cancer presented at the 236th National Meeting of the American Chemical Society (236th-ACS-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top